The cannabinoid CB(2) receptor: a good friend in the gut.
Mammalian tissues express the cannabinoid 1 (CB(1)) receptor and the cannabinoid 2 (CB(2)) receptor, the latter being involved in inflammation and pain. In somatic nerve pathways, the analgesic effects of CB(2) agonism are well documented. Two papers published in the Journal have provided evidence that CB(2) receptor activation inhibits visceral afferent nerve activity in rodents. These exciting findings are discussed in the context of recent data highlighting the emerging role of CB(2) receptor as a critical target able to counteract hypermotility in pathophysiological states, gut inflammation and possibly colon cancer.
Izzo
A A
AA
Endocannabinoid Research Group, Department of Experimental Pharmacology, University of Naples Federico II, Naples, Italy. aaizzo@unina.it
D000818:Animals; D002186:Cannabinoids / Q000494:pharmacology; D005769:Gastrointestinal Motility / Q000187:drug effects / Q000502:physiology; D041981:Gastrointestinal Tract / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects; D009369:Neoplasms / Q000378:metabolism; D043885:Receptor, Cannabinoid, CB2 / Q000378:metabolism*
D002186:Cannabinoids; D043885:Receptor, Cannabinoid, CB2